We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer to Settle Celebrex, Bextra Class Action Suit for $486 Million
Pfizer to Settle Celebrex, Bextra Class Action Suit for $486 Million
A federal judge signed off on a $486 million settlement between Pfizer and the company’s shareholders to end a long-standing class action suit alleging the company misrepresented the cardiovascular risks of its analgesics Celebrex and Bextra.